Platelet eicosanoid biosynthesis

Platelet eicosanoid biosynthesis is the metabolic pathway responsible for the production of bioactive lipid mediators from arachidonic acid within blood platelets [PMID: 25634671]. The most clinically significant product of this pathway is thromboxane A2 (TXA2), which is synthesized through the sequential actions of cyclooxygenase-1 (COX-1) and thromboxane synthase (TXAS) [StatPearls: NBK537079]. TXA2 is a potent agonist that triggers platelet aggregation and vasoconstriction, making it a key driver of both physiological hemostasis and pathological arterial thrombosis [PMID: 11739309]. Another branch of the pathway involves 12-lipoxygenase (12-LOX), which generates 12-hydroxyeicosatetraenoic acid (12-HETE), a mediator involved in inflammatory responses and vascular remodeling [PMID: 21908597]. This pathway is the primary target of antiplatelet therapy, most notably low-dose aspirin, which irreversibly inhibits COX-1 to provide long-lasting protection against myocardial infarction and stroke [PMID: 18497331]. While highly effective for cardiovascular prevention, pharmacological inhibition of this pathway increases the risk of gastrointestinal bleeding and other hemorrhagic events [PMID: 23583256].

Other names

Platelet arachidonic acid metabolismThromboxane A2 synthesis pathwayPlatelet prostaglandin biosynthesis

Inhibition of cyclooxygenase-1 (COX-1) and thromboxane synthase (TXAS) enzymes to prevent the biosynthesis of thromboxane A2, thereby reducing platelet aggregation and thrombotic risk.